Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 9/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.39 |
| ▸ | AXL | P30530 | 9/20 | 0.38 |
| ▸ | MERTK | Q12866 | 8/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 5/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3114543 | 0.90 | AXL (0.40) | METAXLMERTKTYRO3 | |
| SCHEMBL4791159 | 0.79 | AXL (0.40) | METAXLMERTKTYRO3 | |
| SCHEMBL3106648 | 0.77 | AXL (0.69) | METAXLMERTKTYRO3 | |
| SCHEMBL2539583 | 0.75 | KDR (0.61) | METKDR | |
| SCHEMBL3095571 | 0.73 | ROCK2 (0.41) | METKDRAXLMERTKTYRO3 | |
| SCHEMBL13860820 | 0.71 | KDR (0.51) | METKDRAXLMERTKMAPK14 | |
| SCHEMBL3111981 | 0.71 | AXL (0.39) | METAXLMERTKTYRO3 | |
| SCHEMBL4720386 | 0.71 | MET (0.39) | METAXLMERTKTYRO3 | |
| SCHEMBL30975207 | 0.70 | MET (0.54) | TLR7METKDRAXL | |
| SCHEMBL13101890 | 0.69 | MET (0.53) | METKDRAXLMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2001880-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| WO-2007103308-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | TLR8 3057/4885TLR7 2137/4885MET 357/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | TLR8 3057/4885TLR7 2137/4885MET 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.